Adipocyte fatty acid-binding protein levels are associated with left ventricular diastolic dysfunction in morbidly obese subjects

Nutrition and Diabetes

Volumn 4, Issue 2, 2014, Pages

  Baessler, A ^a   Lamounier Zepter, V ^b   Fenk, S ^a   Strack, C ^a   Lahmann, C ^c   Loew, T ^a   Schmitz, G ^d   Bluher M ^e   Bornstein, S R ^b   Fischer, M ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF REGENSBURG   (Germany)

^e UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Diastolic dysfunction; Fatty acid binding protein 4; Metabolic syndrome; Obesity

Indexed keywords

FATTY ACID BINDING PROTEIN 4;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEART LEFT VENTRICLE FUNCTION; HUMAN; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; MALE; METABOLIC SYNDROME X; MORBID OBESITY; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TISSUE DOPPLER IMAGING; WEIGHT CONTROL;

EID: 84906823551     PISSN: None     EISSN: 20444052     Source Type: Journal    
DOI: 10.1038/nutd.2014.3     Document Type: Article

References (33)

1. Maeda K. Role of adiponectin and adipocyte fatty acid binding protein in the metabolic syndrome. Diabetes Res Clin Pract 2007; 77: S17-S22.
2. Kralisch S, Fasshauer M. Adipocyte fatty acid binding protein: A novel adipokine involved in the pathogenesis of metabolic and vascular disease? Diabetologia 2013; 56: 10-21.
3. Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 2008; 7: 489-503.
4. Queipo-Ortuno MI, Escote X, Ceperuelo-Mallafre V, Garrido-Sanchez L, Miranda M, Clemente-Postigo M et al. FABP4 dynamics in obesity: discrepancies in adipose tissue and liver expression regarding circulating plasma levels. PLoS One 2012; 7: e48605.
5. Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE, Spiegelman BM. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 1996; 274: 1377-1379.
6. Tuncman G, Erbay E, Hom X, De Vivo I, Campos H, Rimm EB et al. A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease. Proc Natl Acad Sci USA 2006; 103: 6970-6975.
7. Stejskal D, Karpisek M. Adipocyte fatty acid binding protein in a Caucasian population: A new marker of metabolic syndrome? Eur J Clin Invest 2006; 36: 621-625.
8. Xu A, Tso AW, Cheung BM, Wang Y, Wat NM, Fong CH et al. Circulating adipocytefatty acid binding protein levels predict the development of the metabolic syndrome: A 5-year prospective study. Circulation 2007; 115: 1537-1543.
9. Cabre A, Lazaro I, Girona J, Manzanares JM, Marimon F, Plana N et al. Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes. J Lipid Res 2008; 49: 1746-1751.
10. Uysal KT, Scheja L, Wiesbrock SM, Bonner-Weir S, Hotamisligil GS. Improved glucose and lipid metabolism in genetically obese mice lacking aP2. Endocrinology 2000; 141: 3388-3396.
11. Lamounier-Zepter V, Look C, Alvarez J, Christ T, Ravens U, Schunck WH et al. Adipocyte fatty acid-binding protein suppresses cardiomyocyte contraction: A new link between obesity and heart disease. Circ Res 2009; 105: 326-334.
12. Djousse L, Bartz TM, Ix JH, Kochar J, Kizer JR, Gottdiener JS et al. Fatty acid-binding protein 4 and incident heart failure: The cardiovascular health study. Eur J Heart Fail 2013; 15: 394-399.
13. Liu M, Zhou M, Bao Y, Xu Z, Li H, Zhang H et al. Circulating adipocyte fatty acid-binding protein levels are independently associated with heart failure. Clin Sci (Lond) 2013; 124: 115-122.
14. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251-259.
15. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004; 350: 1953-1959.
16. Aljaroudi W, Alraies MC, Halley C, Rodriguez L, Grimm RA, Thomas JD et al. Impact of progression of diastolic dysfunction on mortality in patients with normal ejection fraction. Circulation 2012; 125: 782-788.
17. Engeli S, Utz W, Haufe S, Lamounier-Zepter V, Pofahl M, Traber J et al. Fatty acid binding protein 4 predicts left ventricular mass and longitudinal function in overweight and obese women. Heart 2013; 99: 944-948.
18. Look C, Morano I, Ehrhart-Bornstein M, Bornstein SR, Lamounier-Zepter V. BMS309403 directly suppresses cardiac contractile function. Naunyn Schmiedebergs Arch Pharmacol 2011; 384: 255-263.
19. Baessler A, Strack C, Rousseva E, Wagner F, Bruxmeier J, Schmiedel M et al. Growth-differentiation factor-15 improves reclassification for the diagnosis of heart failure with normal ejection fraction in morbid obesity. Eur J Heart Fail 2012; 14: 1240-1248.
20. Strack C, Baessler A, Wagner F, Bruxmeier J, Yaroslavskii O, Rousseva E et al. Mannose-binding lectin in obesity with different degrees of metabolic syndrome abnormalities: Association with atherogenic and metabolic traits. J Atheroscler Thromb 2012; 19: 539-551.
21. Grundy SM, Brewer Jr HB, Cleeman JI, Smith Jr SC, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-438.
22. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009; 10: 165-193.
23. Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE et al. How to diagnose diastolic heart failure: A consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 28: 2539-2550.
24. Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics 1989; 45: 255-268.
25. Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006; 52: 405-413.
26. Makowski L, Hotamisligil GS. The role of fatty acid binding proteins in metabolic syndrome and atherosclerosis. Curr Opin Lipidol 2005; 16: 543-548.
27. Bao Y, Lu Z, Zhou M, Li H, Wang Y, Gao M et al. Serum levels of adipocyte fatty acid-binding protein are associated with the severity of coronary artery disease in Chinese women. PLoS One 2011; 6: e19115.
28. Cabre A, Valdovinos P, Lazaro I, Bonet G, Bardaji A, Masana L. Parallel evolution of circulating FABP4 and NT-proBNP in heart failure patients. Cardiovasc Diabetol 2013; 12: 72.
29. Maeder MT, Kaye DM. Heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol 2009; 53: 905-918.
30. Kitzman DW. Diastolic heart failure in the elderly. Heart Fail Rev 2002; 7: 17-27.
31. Mogelvang R, Sogaard P, Pedersen SA, Olsen NT, Marott JL, Schnohr P et al. Cardiac dysfunction assessed by echocardiographic tissue Doppler imaging is an independent predictor of mortality in the general population. Circulation 2009; 119: 2679-2685.
32. Terra X, Quintero Y, Auguet T, Porras JA, Hernandez M, Sabench F et al. FABP 4 is associated with inflammatory markers and metabolic syndrome in morbidly obese women. Eur J Endocrinol 2011; 164: 539-547.
33. Karakas SE, Almario RU, Kim K. Serum fatty acid binding protein 4, free fatty acids, and metabolic risk markers. Metabolism 2009; 58: 1002-1007.